These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. Cohen S; Myneni S; Batt A; Guerrero J; Brumm J; Chung S MAbs; 2021; 13(1):1898831. PubMed ID: 33729092 [TBL] [Abstract][Full Text] [Related]
3. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. Karle A; Spindeldreher S; Kolbinger F MAbs; 2016; 8(3):536-50. PubMed ID: 26817498 [TBL] [Abstract][Full Text] [Related]
4. Applying MAPPs Assays to Assess Drug Immunogenicity. Karle AC Front Immunol; 2020; 11():698. PubMed ID: 32373128 [TBL] [Abstract][Full Text] [Related]
5. Preclinical immunogenicity risk assessment of biotherapeutics using CD4 T cell assays. Walsh RE; Nix A; Ackaert C; Mazy A; Schockaert J; Pattyn S; Malherbe L Front Immunol; 2024; 15():1406040. PubMed ID: 38863708 [TBL] [Abstract][Full Text] [Related]
6. Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. Unterman A; Sumida TS; Nouri N; Yan X; Zhao AY; Gasque V; Schupp JC; Asashima H; Liu Y; Cosme C; Deng W; Chen M; Raredon MSB; Hoehn KB; Wang G; Wang Z; DeIuliis G; Ravindra NG; Li N; Castaldi C; Wong P; Fournier J; Bermejo S; Sharma L; Casanovas-Massana A; Vogels CBF; Wyllie AL; Grubaugh ND; Melillo A; Meng H; Stein Y; Minasyan M; Mohanty S; Ruff WE; Cohen I; Raddassi K; ; Niklason LE; Ko AI; Montgomery RR; Farhadian SF; Iwasaki A; Shaw AC; van Dijk D; Zhao H; Kleinstein SH; Hafler DA; Kaminski N; Dela Cruz CS Nat Commun; 2022 Jan; 13(1):440. PubMed ID: 35064122 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates. Nabhan M; Pallardy M; Turbica I Front Immunol; 2020; 11():725. PubMed ID: 32431697 [TBL] [Abstract][Full Text] [Related]
8. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development. Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796 [TBL] [Abstract][Full Text] [Related]
9. The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques. Wang Y; Whittall T; Rahman D; Bunnik EM; Vaughan R; Schøller J; Bergmeier LA; Montefiori D; Singh M; Schuitemaker H; Lehner T PLoS One; 2012; 7(4):e34433. PubMed ID: 22514633 [TBL] [Abstract][Full Text] [Related]
10. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283 [TBL] [Abstract][Full Text] [Related]
11. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. Eller MA; Blom KG; Gonzalez VD; Eller LA; Naluyima P; Laeyendecker O; Quinn TC; Kiwanuka N; Serwadda D; Sewankambo NK; Tasseneetrithep B; Wawer MJ; Gray RH; Marovich MA; Michael NL; de Souza MS; Wabwire-Mangen F; Robb ML; Currier JR; Sandberg JK PLoS One; 2011 Apr; 6(4):e18779. PubMed ID: 21526194 [TBL] [Abstract][Full Text] [Related]